# Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630)

> **NCT00871910** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 81 (actual)

## Conditions studied

- Solid Tumors
- Lymphoma, Non-Hodgkin
- Multiple Myeloma

## Interventions

- **DRUG:** SCH 727965
- **DRUG:** SCH 727965
- **DRUG:** SCH 727965
- **DRUG:** SCH 727965
- **DRUG:** Aprepitant
- **DRUG:** Ondansetron
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT00871910
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10-11
- **Primary completion:** 2010-02-22
- **Final completion:** 2010-02-22
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2017-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00871910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00871910, "Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00871910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*